A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs CERC 301 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Cerecor
  • Most Recent Events

    • 16 May 2016 According to Cerecor media release, top-line data are expected in the first half of 2017, as additional time will be necessary to complete enrollment in that study.
    • 20 Mar 2015 Results published in the Media Release.
    • 20 Mar 2015 Primary endpoint (HDRS-17 after 7 days of dosing with study drug) has not been met, according to Cerecor media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top